LONDON, Sept. 2, 2020 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe after successfully receiving CE mark certification. The NOVOSTITCH PRO Meniscal Repair System expands meniscal repair options to around 600,0001 European patients annually where the only previous option was removal.
Meniscal tears are one of the most common orthopaedic injuries,2 with 70% of patients expecting a repair,3 yet only 15% actually getting one. Instead, the majority may receive a partial removal or a full meniscectomy4,5,6 which has been shown to increase the risk of osteoarthritis in the knee by 53% compared to baseline.7 The NOVOSTITCH PRO Meniscal Repair System is designed to provide surgeons with a means to treat more meniscal tears with repair and close the gap on meniscectomy.
The first clinical experiences in Europe, Middle East and Africa have been well received. Dr. Ramon Cugat from Hospital Quiron Barcelona commented, “The NOVOSTITCH PRO Meniscal Repair System represents a versatile and essential tool allowing surgeons the ability to repair meniscal tears that other devices, up until now, couldn’t.”
Further, Dr. Ricardo Cueller from Policlínica Gipuzkoa Hospital, (País Vasco) offered a similar report after his first case explaining, “The NOVOSTITCH PRO Meniscal Repair System provided great versatility and a new way for surgeons to treat meniscal tears. We are excited by the possibility of providing meniscal repair to more patients.”
The NOVOSTITCH PRO Meniscal Repair System enables surgeons to place stitches arthroscopically in tight joint compartments, utilizing a meniscus-to-meniscus circumferential compression stitch allowing repair of tears that may not have been repaired in the past.8 The system includes an ergonomic and intuitive handle design and well-defined visual cues for precise stitch placement and control.
In the UK, early clinical experiences were also positive. Mr. David Hahn, The Park Hospital, Nottingham exclaimed “The NOVOSTITCH PRO will allow me to address more meniscal tears than previously thought possible. I look forward to using this promising device at all my locations.”
“We are delighted to be able to offer this ground-breaking technology to surgeons in Europe,” commented Terry Byca, Vice President, Marketing Sports Medicine EMEA, Smith+Nephew. “The NOVOSTITCH PRO Meniscal Repair System’s unique capabilities, along with our industry leading All Tears, All Repairs Meniscal Repair portfolio brings us closer to making repair, not removal, the standard-of-care for meniscal tears.”
The NOVOSTITCH PRO Meniscal Repair System is commercially available for sale in the US, Europe, Middle East, Africa and select countries.
- Smith + Nephew Internal Data. 2020
- Mordecai SC, Al-Hadithy N, Ware HE, Gupte CM. Treatment of meniscal tears: An evidence based approach. World Journal of Orthopedics 2014;5(3):233-241.
- Brophy RH, Gefen AM, Matava MD, et al. Understanding of Meniscus Injury and Expectations of Meniscus Surgery in Patients Presenting for Orthopaedic Care. Arthroscopy 2015;31(12):2295-2300.
- 2018 SmartTRAK US Meniscal Repair Fixation market report.
- Abrams GD, Frank RM, Gupta AK, Harris JD, McCormick FM, Cole BJ. Trends in Meniscus Repair and Meniscectomy in the United States, 2005-2011. AJSM 2013;41(10):2333-9.
- Katano H, Koga H, Ozeki N, et al. Trends in isolated meniscus repair and meniscectomy in Japan, 2011-2016, Int. J. Orthop Sci. 2018;23(4):678-81.
- Papalia R, Del AD, Osti L, Denaro V. Meniscectomy as a risk factor for knee osteoarthritis: a systematic review. British Medical Bulletin. 2011;99:89-106.
- Saliman, JD. The Circumferential Compression Stitch for Meniscus Repair. Arthroscopy Techniques 2013;2(3):e257-e264.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc